Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
Alzheimer's Disease - From Fundamental Insights to Light at the End of the Translational Tunnel (2014Q8)
New Frontiers in Neurodegenerative Disease Research (2013J8)
ApoE, Alzheimer's and Lipoprotein Biology (2012Q5)

Web Desc
Alzheimer's Disease Beyond Abeta Organizer(s): JoAnne McLaurin and Tony Wyss-Coray Date: January 10 - 15, 2010 Location: Copper Mountain Resort, Copper Mountain, CO, USA Sponsored by Takeda Pharmaceutical Company Limited Summary of Meeting: By 2010 many of the clinical trials presently underway targeting Abeta will have been completed or far enough along the pathway that we will have a better understanding of the benefit and limitations of this approach. This leads us to consider what are the next targets that will need to be addressed to fully treat and prevent Alzheimer’s disease. The objective of this meeting is therefore to stimulate and promote a discussion beyond Abeta as a key factor and therapeutic target in Alzheimer's Disease. This objective will be equally important whether therapeutic approaches targeting Abeta are successful or not, to either complement and expand successful Abeta therapies or to initiate a paradigm shift. In particular, we would like to discuss the generation of alternative models to study Alzheimer's Disease, and highlight several exciting areas of research including the role of synaptic dysfunction, neuronal regeneration, the immune system, and protein degradation in Alzheimer's Disease. Scholarship Deadline: September 15 2009 Discounted Abstract Deadline: September 15 2009 Abstract Deadline: October 13 2009 Discounted Registration Deadline: November 10 2009 We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Avid Radiopharmaceuticals, Inc. Genentech, Inc. Lilly UK Pfizer Inc. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: We gratefully acknowledge the generous grant for this conference provided by: National Institute on Aging (NIA) Grant No. 1R13AG034733-01 We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Alzheimer's Disease Beyond Abeta

Organizer(s): JoAnne McLaurin and Tony Wyss-Coray

Date: January 10 - 15, 2010
Location: Copper Mountain Resort, Copper Mountain, CO, USA

Sponsored by Takeda Pharmaceutical Company Limited

Summary of Meeting:

By 2010 many of the clinical trials presently underway targeting Abeta will have been completed or far enough along the pathway that we will have a better understanding of the benefit and limitations of this approach. This leads us to consider what are the next targets that will need to be addressed to fully treat and prevent Alzheimer’s disease. The objective of this meeting is therefore to stimulate and promote a discussion beyond Abeta as a key factor and therapeutic target in Alzheimer's Disease. This objective will be equally important whether therapeutic approaches targeting Abeta are successful or not, to either complement and expand successful Abeta therapies or to initiate a paradigm shift. In particular, we would like to discuss the generation of alternative models to study Alzheimer's Disease, and highlight several exciting areas of research including the role of synaptic dysfunction, neuronal regeneration, the immune system, and protein degradation in Alzheimer's Disease.

Scholarship Deadline: September 15 2009

Discounted Abstract Deadline: September 15 2009

Abstract Deadline: October 13 2009

Discounted Registration Deadline: November 10 2009

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Avid Radiopharmaceuticals, Inc.

Genentech, Inc.

Lilly UK

Pfizer Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

We gratefully acknowledge the generous grant for this conference provided by:

National Institute on Aging (NIA)
Grant No. 1R13AG034733-01

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, January 10 \| 3:00PM - 7:30PM Registration Room: Kokopelli's
Sunday, January 10 \| 6:30PM - 7:30PM Refreshments Room: Kokopelli's
Sunday, January 10 \| 7:30PM - 8:30PM Keynote Address I Room: Big Horn B Speaker 1 of 2 * JoAnne McLaurin, University of Toronto, Canada
Sunday, January 10 \| 7:30PM - 8:30PM Keynote Address I Room: Big Horn B Speaker 2 of 2 Dora Games, Neotope Biosciences, USA Issues and Advances in the Development of Immunotherapeutic Approaches for Alzheimer's Disease
Sunday, January 10 \| 8:30PM - 9:30PM Keynote Address II Room: Big Horn B Speaker 1 of 2 * Tony Wyss-Coray, Stanford University School of Medicine, USA
Sunday, January 10 \| 8:30PM - 9:30PM Keynote Address II Room: Big Horn B Speaker 2 of 2 Lennart Mucke, Gladstone Institutes and University of California, San Francisco, USA Strategies to Block Alzheimer's Disease-Associated Neuronal Dysfunction
Monday, January 11 \| 7:00AM - 8:00AM Breakfast Room: Kokopelli's
Monday, January 11 \| 8:00AM - 11:00AM Remodeling Alzheimer's Disease: An Academic Perspective Room: Big Horn B Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans? Speaker 1 of 5 * Lennart Mucke, Gladstone Institutes and University of California, San Francisco, USA
Monday, January 11 \| 8:00AM - 11:00AM Remodeling Alzheimer's Disease: An Academic Perspective Room: Big Horn B Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans? Speaker 2 of 5 Todd Eliot Golde, Mayo Clinic Jacksonville, USA Preclincial Studies of Alzheimer's Disease and the Treatment versus Prevention Paradox
Monday, January 11 \| 8:00AM - 11:00AM Remodeling Alzheimer's Disease: An Academic Perspective Room: Big Horn B Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans? Speaker 3 of 5 Bart De Strooper, University College London, UK Dysregulation of the microRNA network in sporadic Alzheimer's disease
Monday, January 11 \| 8:00AM - 11:00AM Remodeling Alzheimer's Disease: An Academic Perspective Room: Big Horn B Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans? Speaker 4 of 5 Roxana Octavia Carare, University of Southampton, UK Perivascular Drainage of Abeta and the Pathology of CAA
Monday, January 11 \| 8:00AM - 11:00AM Remodeling Alzheimer's Disease: An Academic Perspective Room: Big Horn B Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans? Speaker 5 of 5 William J. Jagust, University of California, Berkeley, USA Structural and Neurochemical Changes within the CNS during Aging and AD in Aging and AD
Monday, January 11 \| 9:20AM - 9:40AM Coffee Break Room: Kokopelli's
Monday, January 11 \| 11:00AM - 1:00PM Poster Setup Room: Big Horn C
Monday, January 11 \| 11:00AM - 11:00AM On Own for Lunch and Recreation
Monday, January 11 \| 1:00PM - 10:00PM Poster Viewing Room: Big Horn C
Monday, January 11 \| 4:30PM - 5:00PM Coffee Available Room: Kokopelli's
Monday, January 11 \| 5:00PM - 7:00PM Remodeling Alzheimer's Disease II: An Industry Perspective Room: Big Horn B Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets. Speaker 1 of 4 * Dora Games, Neotope Biosciences, USA
Monday, January 11 \| 5:00PM - 7:00PM Remodeling Alzheimer's Disease II: An Industry Perspective Room: Big Horn B Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets. Speaker 2 of 4 Marc Tessier-Lavigne, Stanford University, USA APP-DR6 Signaling in Axon Development, Regeneration, and Degeneration
Monday, January 11 \| 5:00PM - 7:00PM Remodeling Alzheimer's Disease II: An Industry Perspective Room: Big Horn B Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets. Speaker 3 of 4 Menelas N. Pangalos, AstraZeneca, UK Beyond Abeta Based Therapies: Developing Novel Modulators of Neurotransmission
Monday, January 11 \| 5:00PM - 7:00PM Remodeling Alzheimer's Disease II: An Industry Perspective Room: Big Horn B Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets. Speaker 4 of 4 Amie L. Phinney, Solvay Pharmaceuticals, Netherlands Short Talk: The Impact of Biomarkers on Alzheimer’s Disease Drug Discovery
Monday, January 11 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Kokopelli's
Monday, January 11 \| 7:30PM - 10:00PM Poster Session 1 Room: Big Horn C
Tuesday, January 12 \| 7:00AM - 8:00AM Breakfast Room: Kokopelli's
Tuesday, January 12 \| 8:00AM - 11:00AM Alzheimer's and Synaptic/Neuronal Disfunction Room: Big Horn B How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present. Speaker 1 of 6 * William E. Van Nostrand, Stony Brook University, USA
Tuesday, January 12 \| 8:00AM - 11:00AM Alzheimer's and Synaptic/Neuronal Disfunction Room: Big Horn B How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present. Speaker 2 of 6 Sheena Josselyn, Hospital for Sick Children, Canada Cognitive Deficits in a Mouse Model of Alzheimer's Disease: The Role of CREB
Tuesday, January 12 \| 8:00AM - 11:00AM Alzheimer's and Synaptic/Neuronal Disfunction Room: Big Horn B How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present. Speaker 3 of 6 Ottavio Arancio, Columbia University Medical Center, USA Amyloid-beta: From Physiology to Pathology
Tuesday, January 12 \| 8:00AM - 11:00AM Alzheimer's and Synaptic/Neuronal Disfunction Room: Big Horn B How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present. Speaker 4 of 6 Steffany A.L. Bennett, University of Ottawa, Canada Phospholipid Mediators of Synaptic Dysfunction
Tuesday, January 12 \| 8:00AM - 11:00AM Alzheimer's and Synaptic/Neuronal Disfunction Room: Big Horn B How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present. Speaker 5 of 6 Guojun Bu, Mayo Clinic, USA ApoE and its Receptor in Brain Lipid Metabolism in AD
Tuesday, January 12 \| 8:00AM - 11:00AM Alzheimer's and Synaptic/Neuronal Disfunction Room: Big Horn B How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present. Speaker 6 of 6 Cynthia A. Massaad, Baylor College of Medicine, USA Short Talk: Mitochondrial Free Radicals Play a Critical Role in Alzheimer’s Disease-Related Blood Flow and Axonal Transport Deficits Pathology
Tuesday, January 12 \| 9:20AM - 9:40AM Coffee Break Room: Kokopelli's
Tuesday, January 12 \| 11:00AM - 11:00AM On Own for Lunch and Recreation
Tuesday, January 12 \| 11:00AM - 1:00PM Poster Setup Room: Big Horn C
Tuesday, January 12 \| 1:00PM - 10:00PM Poster Viewing Room: Big Horn C
Tuesday, January 12 \| 4:30PM - 5:00PM Coffee Available Room: Kokopelli's
Tuesday, January 12 \| 5:00PM - 7:00PM Alzheimer's Disease and Neuronal Regeneration Room: Big Horn B Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease? Speaker 1 of 5 * Bruce T. Lamb, Indiana University School of Medicine, USA
Tuesday, January 12 \| 5:00PM - 7:00PM Alzheimer's Disease and Neuronal Regeneration Room: Big Horn B Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease? Speaker 2 of 5 Frank Longo, Stanford School of Medicine, USA Small Molecule p75 Receptor Ligands Inhibit Abeta-Induced Degeneration, Synaptic Dysfunction and Cognitive Loss
Tuesday, January 12 \| 5:00PM - 7:00PM Alzheimer's Disease and Neuronal Regeneration Room: Big Horn B Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease? Speaker 3 of 5 Daniel A. Peterson, Rosalind Franklin University, Chicago Medical School, USA The Contribution of Neurogenesis in Repairing the Aging Brain
Tuesday, January 12 \| 5:00PM - 7:00PM Alzheimer's Disease and Neuronal Regeneration Room: Big Horn B Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease? Speaker 4 of 5 Stephen M. Strittmatter, Yale University, USA Beyond (Downstream of) Abeta: NgR and PrP
Tuesday, January 12 \| 5:00PM - 7:00PM Alzheimer's Disease and Neuronal Regeneration Room: Big Horn B Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease? Speaker 5 of 5 Patrick A. Lewis, University of Reading, UK Short Talk: Investigating Lewy Body Disease with Human Neuronal Cells
Tuesday, January 12 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Kokopelli's
Tuesday, January 12 \| 7:30PM - 10:00PM Poster Session 2 Room: Big Horn C
Wednesday, January 13 \| 7:00AM - 8:00AM Breakfast Room: Kokopelli's
Wednesday, January 13 \| 8:00AM - 11:00AM Alzheimer's and the Immune System Room: Big Horn B What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta. Speaker 1 of 6 * Andrea J. Tenner, University of California, Irvine, USA
Wednesday, January 13 \| 8:00AM - 11:00AM Alzheimer's and the Immune System Room: Big Horn B What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta. Speaker 2 of 6 Richard M. Ransohoff, Third Rock Ventures, USA Microglia, Monocytes and Macrophages
Wednesday, January 13 \| 8:00AM - 11:00AM Alzheimer's and the Immune System Room: Big Horn B What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta. Speaker 3 of 6 Terrence Town, Cedars-Sinai University of California Los Angeles, USA Inflammation and Innate Immunity in Alzheimer's Disease
Wednesday, January 13 \| 8:00AM - 11:00AM Alzheimer's and the Immune System Room: Big Horn B What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta. Speaker 4 of 6 Josef Priller, Charité – Universitätsmedizin Berlin, Germany Bone Marrow-Derived Cells in Models of Alzheimer's Disease
Wednesday, January 13 \| 8:00AM - 11:00AM Alzheimer's and the Immune System Room: Big Horn B What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta. Speaker 5 of 6 Joseph El Khoury, Massachusetts General Hospital, USA Chemokines and Mononuclear Phagocytes recruited in AD
Wednesday, January 13 \| 8:00AM - 11:00AM Alzheimer's and the Immune System Room: Big Horn B What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta. Speaker 6 of 6 Marie E. Benoit, University of California, Irvine regents, USA Short Talk: Neuroprotective Pathways Stimulated by the Complement Protein C1q in Neurons
Wednesday, January 13 \| 9:20AM - 9:40AM Coffee Break Room: Kokopelli's
Wednesday, January 13 \| 11:00AM - 1:00PM Poster Setup Room: Big Horn C
Wednesday, January 13 \| 11:00AM - 11:00AM On Own for Lunch and Recreation
Wednesday, January 13 \| 1:00PM - 10:00PM Poster Viewing Room: Big Horn C
Wednesday, January 13 \| 4:30PM - 5:00PM Coffee Available Room: Kokopelli's
Wednesday, January 13 \| 5:00PM - 7:00PM Alzheimer's and Protein Degradation Room: Big Horn B What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation? Speaker 1 of 5 * Terrence Town, Cedars-Sinai University of California Los Angeles, USA
Wednesday, January 13 \| 5:00PM - 7:00PM Alzheimer's and Protein Degradation Room: Big Horn B What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation? Speaker 2 of 5 Jeffery W. Kelly, The Scripps Research Institute, USA Proteostasis
Wednesday, January 13 \| 5:00PM - 7:00PM Alzheimer's and Protein Degradation Room: Big Horn B What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation? Speaker 3 of 5 Kent B. Matlack, Whitehead Institute for Biomedical Research, USA Using Simple Cells to Model Complex Diseases
Wednesday, January 13 \| 5:00PM - 7:00PM Alzheimer's and Protein Degradation Room: Big Horn B What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation? Speaker 4 of 5 Zhenyu Yue, Mount Sinai Medical Center, USA Autophagy: Cell Self-Eating in Alzheimer's Disease
Wednesday, January 13 \| 5:00PM - 7:00PM Alzheimer's and Protein Degradation Room: Big Horn B What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation? Speaker 5 of 5 Gizem Donmez, Tufts University School of Medicine, USA Short Talk: SIRT1 Suppresses Alzheimer´s Disease by Activating the Alpha Secretase Gene ADAM10 in APPswe, PSEN1dE9 Mouse Model
Wednesday, January 13 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Kokopelli's
Wednesday, January 13 \| 7:30PM - 10:00PM Poster Session 3 Room: Big Horn C
Thursday, January 14 \| 7:00AM - 8:00AM Breakfast Room: Kokopelli's
Thursday, January 14 \| 8:00AM - 11:00AM Alzheimer's Disease and Diagnostics Room: Big Horn B Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets? Speaker 1 of 5 Daniel M. Skovronsky, Eli Lilly and Company, USA PET Radiopharmaceuticals for Diagnosis of Dementias
Thursday, January 14 \| 8:00AM - 11:00AM Alzheimer's Disease and Diagnostics Room: Big Horn B Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets? Speaker 2 of 5 Holly Soares, Bristol-Myers Squibb, USA Multiplex Panels as Diagnostic Tools in Alzheimer’s Disease
Thursday, January 14 \| 8:00AM - 11:00AM Alzheimer's Disease and Diagnostics Room: Big Horn B Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets? Speaker 3 of 5 Neill Graff-Radford, Mayo Clinic, USA What have we learned from plasma Abeta?
Thursday, January 14 \| 8:00AM - 11:00AM Alzheimer's Disease and Diagnostics Room: Big Horn B Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets? Speaker 4 of 5 * Tony Wyss-Coray, Stanford University School of Medicine, USA The Plasma Communicome of Normal Aging and Dementia
Thursday, January 14 \| 8:00AM - 11:00AM Alzheimer's Disease and Diagnostics Room: Big Horn B Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets? Speaker 5 of 5 Alice M. Wyrwicz, NorthShore University HealthSystem, USA Short Talk: Diffusion Tensor Imaging as a Potential Biomarker of Dendritic Alterations in Mouse Models of AD
Thursday, January 14 \| 9:20AM - 9:40AM Coffee Break Room: Kokopelli's
Thursday, January 14 \| 11:00AM - 11:00AM On Own for Lunch and Recreation
Thursday, January 14 \| 4:30PM - 5:00PM Coffee Available Room: Kokopelli's
Thursday, January 14 \| 5:00PM - 7:00PM Alzheimer's Disease and Therapeutics Room: Big Horn B If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs? Speaker 1 of 4 Kullervo Hynynen, Sunnybrook Health Sciences Centre, Canada MRI Guided Ultrasound Delivery of Drugs to the CNS
Thursday, January 14 \| 5:00PM - 7:00PM Alzheimer's Disease and Therapeutics Room: Big Horn B If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs? Speaker 2 of 4 Valerie Cullen, Link Medicine Corp, USA A New Therapeutic Strategy for Neurodegeneration
Thursday, January 14 \| 5:00PM - 7:00PM Alzheimer's Disease and Therapeutics Room: Big Horn B If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs? Speaker 3 of 4 * JoAnne McLaurin, University of Toronto, Canada Small Molecule Therapy for Alzheimer's Disease
Thursday, January 14 \| 5:00PM - 7:00PM Alzheimer's Disease and Therapeutics Room: Big Horn B If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs? Speaker 4 of 4 Linda J. Van Eldik, University of Kentucky, USA Short Talk: Targeting Glia-Neuron Interactions that Result in Synaptic Dysfunction as a Drug Discovery Strategy for Alzheimer’s Disease
Thursday, January 14 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Kokopelli's
Thursday, January 14 \| 8:00PM - 11:00PM Entertainment Room: Big Horn C
Thursday, January 14 \| 8:00PM - 11:00PM Cash Bar Room: Big Horn C
Friday, January 15 \| 10:25AM - 10:25AM Departure *Session Chair.